RecruitingPhase 2NCT04838652
Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma
Studying Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Cologne
- Principal Investigator
- Andreas Engert, Prof.1st Department of Medicine, Cologne Universit Hospital
- Intervention
- Pembrolizumab plus Chemotherapy (ICE or DHAP)(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- 1st Department of Medicine, Cologne University Hospital, Cologne, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04838652 on ClinicalTrials.govOther trials for Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07374068Prognostic Model of Elderly Hodgkin Lymphoma in ChinaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT07356882European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin LymphomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06848569Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II StudySun Yat-sen University
- RECRUITINGPHASE2, PHASE3NCT06563245Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentChildren's Cancer Group, China
- RECRUITINGPHASE2NCT05900765A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaSun Yat-sen University
- RECRUITINGNCT06822855Changing Paragidms In The Prognostic Assessment Of Hodgkin LymphomaAzienda USL Reggio Emilia - IRCCS
- ACTIVE NOT RECRUITINGPHASE1NCT04640779Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaMayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT04268706Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Tessa Therapeutics